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The antidiuretic hormone argmme vasopressin could
contribute to both the vasoconstriction and impaired
water handling frequently found in patients with conges-
tive heart failure. In order to determine basal levels for
vasopressin in this condition, plasma vasopressin was
measured by radioimmunoassay in a group of31 patients
with advanced congestive heart failure. At the same time,
plasma norepinephrine, plasma renin activity and nu-
merous hemodynamic variables were also measured. In
a subgroup of patients, the response of vasopressin to
hemodynamic changes induced by nitroprusside infusion
and to inhibition of the renin-angiotensin system with
captopril was studied. The basal vasopressin levels in
the patients were compared with those obtained from 51
comparably aged normal subjects. The mean vasopres-
sin level (± standard error of the mean) in the patients
was 9.5 ± 0.89 pg/ml as compared with 4.7 ± 0.66
(probability [p] < 0.001) in the normal subjects. Serum
sodium was 137 ± 0.56 mEqlIiter. The vasopressin level
did not correlate with any hemodynamic variable and
was increased to the same degree in patients with both
Vasoconstrictor mechanisms frequently are activated in pa-
tients with congestive heart failure. Both increased sym-
pathetic tone and increased activity of the renin-angiotensin
system have been demonstrated in this condition (1-3).
Neither the stimulus that activates these systems nor the
physiologic significance of this activation is yet apparent.
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low and normal cardiac index. The vasopressin level
failed to correlate with serum sodium, and was similarly
increased in patients with lowand normal serum sodium.
There was no correlation of vasopressin and plasma nor-
epinephrine, but vasopressin did correlate modestlywith
plasma renin activity (r =0.53, p < 0.02). Acute hemo-
dynamic changes induced by nitroprusside did not in-
fluence vasopressin levels, nor did comparable changes
accompanied by inhibition of the renin-angiotensin sys-
tem with captopril.
Thus, vasopressin levelsmeasured under steady state
conditions are usually increased in patients with conges-
tive heart failure. The increase is not dependent on re-
duced cardiac index. There appears to be an abnormality
in the relation between vasopressin and serum sodium
in some persons and vasopressin does not respond to
acute hemodynamic changes with or without the inhi-
bition of the renin-angiotensin system. The mechanisms
causing increased vasopressin levels and their biologic
importance in congestive heart failure remain to be
defined.
Vasoconstriction may begin as part of a compensatory re-
sponse to impaired cardiac function, but it may also con-
tribute to the pathophysiology of congestive heart failure by
inappropriately increasing vascular impedance and promot-
ing excessive salt and water retention (4).
The antidiuretic hormone, arginine vasopressin, is a pow-
erful endogenous vasoconstrictor (5-8) which has been little
studied in patients with congestive heart failure, in part
because of the unavailability of reliable assay techniques
until the last several years. A previous report using a bioas-
say (9) has suggested that vasopressin levels may sometimes
be abnormal in this condition. This report, together with the
observation of the higher levels of other vasoconstrictor
substances in congestive heart failure and the known pro-
pensity of patients with congestive heart failure to become
hyponatremic, led us to measure vasopressin levels in pa-
tients with congestive heart failure using a sensitive and
specific radioimmunoassay for this hormone (10). The de-
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velopment of selective blockers of the vascular and renal
effects of vasopressin gives additional impetus to the study
of this hormone in disease states because it may become
possible to modify its effects if abnormalities are demon-
strated (5,8, II) . This paper reports our initial findings in
31 patients with heart failure and demonstrates that vaso-
pressin levels, like those of plasma norepinephrine and renin
activity, are increased in patients with this condition.
Methods
Patient selection. Thirty-one patients with clear evi-
dence of congestive heart failure on the basis of typical
history and physical findings formed the basic study pop-
ulation . All had supporting noninvasive evidence for the
syndrome including an enlarged heart on chest X-ray ex-
amination and either depressed fractional shortening by M-
mode echocardiography or a depressed ejection fraction by
radionuclide scan. There were 29 men and 2 women , and
the mean age was 55 years . The cause of the heart failure
was either primary or ischemic cardiomyopathy . No patient
with hypertension requiring treatment was included and no
patient was studied within 3 months of myocardial infarc-
tion. All patients were taking diuretic drugs and most were
taking digitalis and vasodilating drugs as well.
Protocol. After giving informed consent, patients were
admitted to a clinical research unit. Baseline blood samples
for hematologic and blood chemistry studies were obtained.
All diuretic and vasodilating drugs were then withheld for
at least 48 hours. Administration of digitalis and antiar-
rhythmic drugs was continued if the patient was taking such
medication. One or two daily morning supine plasma sam-
ples for vasopressin were obtained in some patients while
they were not receiving diuretic and vasodilating drugs.
During the observation period, patients were maintained on
a low salt diet (500 mg to 2 g, depending on clinical as-
sessment of the severity of disease) .
The night before planned invasive study, serum electro-
lytes were rechecked. If clinical status and electrolytes were
stable , the patient was taken at 8 a.m . the next day to a
special procedure room where a Swan-Ganz thermodilution
catheter and an arterial cannula were inserted using per-
cutaneous technique. After a 30 to 60 minute rest period
following catheter insertion, measurements were made of
heart rate , blood pressure, right atrial pressure, pulmonary
artery and capillary wedge pressures and cardiac output.
These measurements were repeated 15 minutes later and if
the two sets of values differed by 10% or less, they were
averaged and accepted as basal. At this lime, blood was
drawn for measuring vasopressin, plasma norepinephrine,
plasma renin activity and in most patients, electrolytes. The
results of these determinations were used to compute the
mean values for each variable and substance measured and
in the analysis of their interrelations.
Controlgroup. Blood from 51 normal volunteer subjects
(mean age 46 years) was obtained by venipuncture after 30
minutes of supine rest in the morning after an overnight fast
similar to that observed by the patients. All subjects were
on a normal diet and were clinically free of heart disease
or hypertension.
Nitroprusside and captopril studies. In patients with heart
failure, we also wished to examine the acute effects of
alterations in nonosmotic variables known to influence the
control of vasopressin release. We were particularly inter-
ested in the possibility that angiotensin II, a known short-
term (12), but perhaps not long-term (13) regulator of vaso-
pressin levels, might be playing a role in sustaining vaso-
pressin levels in this condition if they were increased. There-
fore, we studied the effects of hemodynamic changes produced
by sodium nitroprusside infusion and by the administration
of the angiotensin-converting enzyme inhibitor, captopril ,
in II patients in this series by measuring the response of
vasopressin during peak hemodynamic effects . The nitro-
prusside was given first at 10 /Lg/min and increased every
10 minutes until left ventricular filling pressure was reduced
by approximately 30% unless systolic pressure less than 90
mm Hg occurred earlier. At the peak hemodynamic re-
sponse. generally 60 to 75 minutes after the start of the
infusion, vasopressin levels were measured. After the in-
fusion was stopped and hemodynamic variables returned to
control values , blood was obtained for a recontrol mea-
surement of vasopressin and 25 mg of captopril was then
given . Hemodynamic measurements were made every 15
minutes after ingestion of the drug and blood was sampled
for vasopressin. The sample obtained at peak hemodynamic
response, which varied from 45 to 75 minutes after drug
ingestion, was compared with the recontrol value.
Assay techniques. All blood samples were immediately
centrifuged with the plasma removed and frozen at -4°C.
Vasopressin was analyzed by a sensitive and specific ra-
dioimmunoassay (10) with an intra-assay coefficient of vari-
ation less than 4% and an ability to detect changes in vaso-
pressin as small as 0.2 pg/ml. Plasma norepinephrine was
analyzed radioenzymatically with the Cat-a-kit (Upjohn
Pharmaceuticals) and plasma renin activity was determined
with the radioimmunoassay for the generation of angiotensin
1 (14) . Both of these assays have coefficients of variation
less than 8% in our laboratory .
Statistical analysis. Results of vasopressin levels in pa-
tients and normal subjects were compared using the unpaired
t test. Stability of the daily vasopressin measurements in
the subpopulation of patients studied was assessed by one
way analysis of variance. Correlation coefficients were cal-
culated by the usual methods. Responses to nitroprusside
and captopril were analyzed with the paired t test.
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Results
Figure l. Correlation of plasma vasopressin (AVP) and plasma
norepinephrine (NE) (A)and plasma renin activity (PRA) (B). NS
== not significant; p = probability; r = correlation coefficient.
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subgroup analysis was carried out with blood pressure as it
was normal in all subjects, or with cardiac fi lling pressures
because they were increased in all (in the case of left ven-
tricular filling pressure) or nearly all (in the case of right
atrial pressure) subjects.
Correlation with serum sodium. To furtherexplore the
relation between vasopressin and serum sodium, we clas-
sified patients on the basis of eunatremia or hyponatremia
(defined as sodium < 135 mEq/liter). The results of the
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Table 1. Values for Plasma Vasopressin, Norepinephrine and
Renin Activity in Patients With Congestive Heart Failure and
Normal Subjects
Hemodynamics. The hemodynamic data (mean ± stan-
dard error of the mean) from patients at the time of study
were as follows: heart rate, 81 ± 1.9 beats/min; mean
arterial pressure, 82 ± 1.1 mm Hg; right atrial pressure,
II ± 1.5 mm Hg; left ventricular filling pressure, 26 ±
0.80 mm Hg (estimated fromthe pulmonary capillarywedge
or if not obtainable the pulmonary arterydiastolic pressure);
cardiac index, 2.2 ± 0.07 liters/min per m2 and systemic
vascular resistance, 1,512 ± 58 dynes-s-cm- 5 . As a group
then, these patients had relatively advanced disease on the
basis of hemodynamic measurements.
Plasma vasopressin (Table 1). Plasma vasopressin was
increased in these patients, with the mean level of 9.5 ±
0.89 pg/ml differing from normalat a high levelof statistical
significance. The values for plasmanorepinephrine andplasma
renin activity were also substantially elevated. Serum so-
dium in the patients averaged 137 ± 0.60 mEqlliter.
Fifteen patients had determinations of vasopressin on I
or 2 additional days while not taking medicationand await-
ing hemodynamic study. The range of differences between
vasopressin values for the multiple day determinations was
ot04.2 pg/ml withan average changeof 12.9%. Differences
among multiple day values were not significant by analysis
of variance. Multiple analyses for plasma norepinephrine
and plasma renin activity were not done in this study, but
have previously been shown to be stable under similar cir-
cumstances (2).
Vasopressin levels did not correlate with any hemody-
namic variable or with serum sodium. They also did not
correlatewith plasma norepinephrine. but didcorrelate mod-
erately and significantly with plasma renin activity (Fig. I).
Correlation of vasopressin levels and hemodynamic
values. The possibility that hemodynamic factors were a
determinant of vasopressin levels in the basal state was
further explored by classifying patients on the basis of car-
diac index « or 2': 2.5 liters/min per rrr') . No difference
was observed in vasopressin between groups (Table 2). No
Patients With
Congestive Heart Failure
Normal
Subjects Table 2. Classification of Patients by Cardiac Index
* = p < 0.00 1; t = P < 0.01.
Values are expressed as mean values ± standard error of the mean
There are 31 pauents with congestive heart failure for each variable. In
the normal group. 51 subjects had vasopressin measurements; I I of these
had plasma norepin ephrine and plasma rerun activity measured as well.
Patients are classified according to normal (2: 2.5 luers/rmn per m2)
or low < 2.5 liters/min per m2) cardiac index. Differences 10 vasopressin
are not significant. Values are expressed as mean values ± standard error
of the mean
Group I (n = 22) Group II (n = 9)Vasopressin (pg/ml)
Norepinephrine (pg/ml)
Renin activity (ng/ml per h)
9.5 ± 0.89
599 ± 64
II ± 2.2
4.7 ± 0.66*
196 ± 23t
1.9 :!: 0 .27t Cardiac index (liters/min per m
2)
Vasopressin (pg/rnl)
1.9 :!:: 0 .06
9.6 :!: 1.0
2.8 ± 0. 12
9. 1 :!:: 1.7
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Vasopressin Level (pg/rnl)
Table 3. Classification of Patients by Serum Sodium
Table 4. Response of Vasopressin to Nitroprusside
and Captopril
Vasopressin was measured durin g the peak effect of each intervention .
Differences are not significant. Values are expressed as mean values ±
standard error of the mean.
renin activity when measured under similar circumstances
(2) .
This demonstration of increased vasopressin levels by
radioimmunoassay confirms the findings previously reported
by Yamane (9) (using a bioassay) of increased vasopressin
in some patients with congestive heart failure and bears out
our preliminary observations reported previously (4), al-
though the vasopressin levels in that pilot study of only a
few subjects were slightly higher. Yamane (9) did not fully
characterize his patient population from a hemodynamic
standpoint and did not mention medication that patients may
have been taking at the time of study. Nonetheless, the levels
of vasopressin in Yamane' s patients with "combined right
and left heart failure" were similar to those in our patients
assuming a conversion of microunits to picograms of 0.38
jLU/pg.
Correlation with hemodynamic var iables. Vasopressin
did not correlate with any hemodynamic variable in our
series of patients. This result differs in one respect from the
study of Yamane (9) in which a positive correlation existed
between vasopressin and right atrial pressure. The expla-
nation for the discrepancy may reside in the fact that nearly
all of our patients had high right-sided pressures, whereas
Yamane studied a large group with normal right-sided pres-
sures. In this case, because of a wider range of values for
both vasopressin and right atrial pressure, a significant cor-
relation may have emerged. However, because we do not
know the status of treatment in Yamane's patients , we make
this conclusion with caution, noting that several patients in
our series had elevated right atrial pressure and normal vaso-
pressin levels.
Vasopressin and regulation of peripheral vascular re-
sistance. Whether plasma vasopressin in the range found
in our patients plays a role in the regulation of the peripheral
vascular resistance cannot as yet be commented on with
certainty. There was no correlation of vasopressin with cal-
culated systemic vascular resistance; however , simple cor-
relation techniques may not be adequate to reveal what may
be a highly complex relation between neuroendocrine ac-
tivity and vascular control. For example, although plasma
renin activity at rest usually does not correlate with systemic
vascular resistance, the improvement induced by angioten-
sin-converting enzyme inhibition frequently correlates well
with plasma renin activity (15), suggesting (although con-
verting-enzyme inhibitors may also have other effects) that
increased activity of the renin-angiotensin system does have
pathophysiologic importance in patients with heart failure.
It is also important to note that vasopressin levels in the
moderately increased range have definite vasoactive effects
in dogs, in terms of both the overall vascular resistance (6)
and the distribution of regional cardiac output (7) . Vaso-
pressin in the moderately increased range also has an im-
portant role in blood pressure maintenance in dehydrated
rats (8). Finally, because patients with congestive heart fail-
Peak Effect
11.4 ± 070
11.9 ±1 2
139 ± 0 .56
9.8 ± 1.0
Eunatrerma
Group 2 (n = 2 1)
12.8 ± 1.7
11.4 ± 0 .9
Control Study
132 ± 1.2
9.4 ± 2.2
Hyponatremi a
Group 2 (n = 7)
Sodium (mEqll iter)
Vasopress in (pg/rnl)
vasopressin determination s disclosed no difference between
the groups (Table 3).
EtTect of nitroprusside and captopril. Nitroprusside
and captopril both induced significant hemodynamic changes.
Mean arterial pressure decreased with both drugs (80 ± 2.0
to 70 ± 2.0 mm Hg with nitroprusside, 84 ± 1.9 to 72
± 2.7 mm Hg with captopril) as did right atrial pressure
(9.6 ± 1.9 to 5.0 ± 1.3 mm Hg and 13 ± 1.9 to 8 ±
1.7 mm Hg, respectively), left ventricular filling pressure
(26 ± 2. 1 to 17 ± 2.3 mm Hg and 28 ± 19 to 22 ± 2.0
mm Hg, respectively) and systemic vascular resistance (1,487
± 108 to 1,036 ± 59 dynes's' cm - s, and 1,595 ± 106 to
1,218 ± 88 dynes -s-cm t " , respectively). Cardiac index
increased from 2.1 ± 0.15 to 2.7 ± 0. 16 liters/min per m2
with nitroprusside and from 2. 1 ± 0.22 to 2.4 ± 0.19
liters/min per m2 with captopril. Vasopressin, however, did
not change significantly with either intervention (Table 4).
Patients are classified accordin g to norm al (2: 135 mEq/liter) or low
« 135 mliq/lrter) serum sod ium level. DIfferences 10 vasopress m are not
significant. Values are expressed as mea n values ± standa rd erro r of the
mean
Discussion
Plasma vasopressin in congestive heart failure. These
data demonstrate that plasma vasopressin levels obtained in
a steady clinical state and free for at least 48 hours of the
effects of diuretic and vasodilating drugs are usually in-
creased in patients with congestive heart failure. Further,
these levels are quite stable if measured on a daily basis
under similar conditions. The increase and stability of va-
sopressin levels parallel the increase and stability we have
previously observed with plasma norepinephrine and plasma
Nitroprusside
Captopril
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ure have abnormal baroreflexes (16), it is worth noting that
due to an apparently specific interaction between vasopres-
sin and the sinoaortic baroreflex, the vascular effects of
vasopressin may be exaggerated when this reflex malfunc-
tions or is removed (6). Thus, data will be needed either
on the effects of inhibiting the pressor actions of vasopressin
or on the vascular sensitivity to vasopressin in patients with
heart failure before we know what, if any, role vasopressin
plays in the regulation of the peripheral resistance in this
condition.
Relation of vasopressin to serum sodium and water
balance. The nature of the relation between vasopressin
and disturbed water balance in congestive heart failure is
also not clear. We did not find a correlation between vaso-
pressin and serum sodium in this group of patients, and
vasopressin levels were the same whether patients had low
or normal sodium (Table 3). There is, therefore, a failure
of vasopressin to suppress in the face of hyponatremia in
some patients with congestive heart failure (as noted also
by Szatolowicz et al.[17]). However, it is questionable whether
nonsuppressed vasopressin itself actually induces hypona-
tremia in most patients, as most of our patients had normal
sodium despite increased vasopressin levels. It is possible
that in some patients, incompletely suppressed vasopressin
along with other factors, such as impaired distal delivery
of sodium and perhaps increased water intake due to the
dipsogenic effects of increased angiotensin II, may combine
to cause a low serum sodium level (18,19). Serial studies
of osmolar changes and vasopressin levels in heart failure
will be needed to clarify these issues.
Mechanisms of increased vasopressin in congestive
heart failure. Although the mechanism leading to in-
creased vasopressin levels in these patients is not apparent
from this initial descriptive study, some possibilities may
be considered. First, we should exclude the possibililty that
the increase is an artifact due to effects of drugs or the
protocol itself. All patients had been withdrawn from di-
uretic and vasodilator therapy for at least 48 hours to min-
imize drug effects and were clinically stable when studied.
Residual effects of the diuretic drugs cannot be completely
excluded, but grossly elevated cardiac fillingpressures strongly
militate against the possiblility of excessive diuresis leading
to nonosmotic stimulation of vasopressin secretion. Diets
were different in the patients and normal subjects because
of the necessity of maintaining patients on low sodium diets
while not taking diuretic medication, but low sodium diets
do not independently stimulate vasopressin release unless
water is restricted (20). They may, however, stimulate renin
which indirectly, by way of angiotensin II, could stimulate
vasopressin (12). In fact, there was a correlation of vaso-
pressin and plasma renin activity (Fig. I). The lack of an
acute effect of captopril on the vasopressin level, however,
does not support the possibility that high angiotensin II
levels were maintaining the vasopressin level. Furthermore,
the fact that vasopressin also failed to change in response
to similar hemodynamic changes induced by nitroprusside
suggests that the lack of response to inhibition of the genesis
of angiotensin II was not due to offsetting factors working
to increase vasopressin, such as a decrease in mean arterial
pressure. Therefore, it seems unlikely that the protocol diet
influenced the results of the vasopressin determinations,
either directly or indirectly, and it is more likely that both
plasma renin activity and vasopressin are responding to a
similar stimulus in congestive heart failure rather than di-
rectly affecting one another.
Most patients were taking digitalis and some were taking
antiarryhthmic drugs. Experimental studies suggest that dig-
italis, by sensitizing cardiac receptors that influence vaso-
pressin secretion and sympathetic nervous system activity
(21), might actually promote a decrease in plasma vaso-
pressin for any given level of receptor stimulation. No data
are available on the effects of antiarrhythmic drugs.
It is also unlikely that the increase in vasopressin was
due to a nonspecific stress reaction during the procedure.
A rest period was observed after catheterization, patients
were comfortable and at ease at this point of the study and,
most importantly, the determinations made simply by veni-
puncture on noncatheterization days were not significantly
different from those on the day of catheterization in the
patients having multiple determinations. We therefore doubt
that the increase in vasopressin is artifactual more likely it
is a characteristic of the heart failure state as studied here.
Increased vasopressin levels could arise either from in-
creased secretion of hormone or from decreased clearance
ofhormone secreted at a normal rate. The circulatory half-
life of vasopressin is approximately 6 minutes (although
estimates vary) and the hormone is cleared by both hepatic
and renal mechanisms (22). As our patients did not exhibit
decompensated liver disease or renal failure, it is unlikely
that clearance is the major factor although is was not spe-
cifically studied here. Rather, abnormalities in either or both
the osmotic control networks for vasopressin release seem
more likely to be involved. The lack of correlation between
serum sodium and vasopressin in these patients suggests a
possible disruption of the normal osmotic regulatory mech-
anism. This disruption could be primary or secondary to
abnormalities in the nonosmotic control pathways. Both
cardiopulmonary receptors and sinoaortic baroreceptors in-
fluence vasopressin secretion nonosmotically (23,24) and
function of both may be abnormal in congestive heart failure
(16,25).
The lack of response of vasopressin to acute decreases
in both cardiac filling pressure and mean arterial pressure
(Table 4) may indicate that these reflexes are unimportant
modulators of vasopressin release in patients with conges-
tive heart failure. In addition, the observation in the current
study that vasopressin levels under basal conditions are not
confined to patients with hypotension (all of our subjects
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being normotensive) or low cardiac index (Table 2) con-
siderably diminishes the likelihood that these factors playa
role in the maintenance of increased vasopressin in the chronic
state as has been speculated elsewhere (17).
In summary; we have shown that vasopressin levels de-
termined by radiommunoassay are usually increased in pa-
tients with congestive heart failure studied under circum-
stances approximating the basal state. It seems unlikely that
this higher level is due to the concomitant heightened ac-
tivity of the renin-angiotensin system or to hypotension or
reduced cardiac output. There may be an abnormality in the
osmotic regulation of vasopressin in this condition because
low serum sodium may coexist with higher vasopressin lev-
els; conversely, increased vasopressin levels do not always
result in hyponatremia. The precise nature of the derange-
ments in both nonosmotic and osmotic control that may lead
to increased vasopressin in heart failure, as well as the
biologic importance of the increase, remains to be discovered.
We thank Susan Ziesche, Dennis Lura, Terry Cameron, Kathy Gross, Ada
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Belinda Anderson for preparing the manuscript.
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